Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Gabapentin is a potent activator of KCNQ3 and KCNQ5 potassium channels

Rian W Manville and Geoffrey Abbott
Molecular Pharmacology July 18, 2018, mol.118.112953; DOI: https://doi.org/10.1124/mol.118.112953
Rian W Manville
University of California, Irvine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey Abbott
University of California, Irvine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Data Supplement

  • Supplemental Data -

    Supplementary Figure 1 - Effects of Gabapentin on KCNQ2/3 channels

    Supplementary Table 1 - Summary of Effects of Gabapentin on KCNQ2/3 channels. Statistics

    Supplementary Figure 2 - Effects of Pregabalin on KCNQ2/3 channels

    Supplementary Table 2 - Summary of Effects of Pregabalin on KCNQ2/3 channels

    Supplementary Figure 3 - Effects of retigabine on KCNQ2/3 channels

    Supplementary Table 3 - Summary of Effects of retigabine on KCNQ2/3 channels

    Supplementary Figure 4 - Effects of Gabapentin on KCNQ2 channels

    Supplementary Table 4 - Summary of Effects of Gabapentin on KCNQ2 channels

    Supplementary Figure 5 - Effects of Gabapentin on KCNQ3* channels

    Supplementary Table 5 - Summary of Effects of Gabapentin on KCNQ3* channels

    Supplementary Figure 6 - Effects of Gabapentin on KCNQ4 channels

    Supplementary Table 6 - Summary of Effects of Gabapentin on KCNQ4 channels

    Supplementary Figure 7 - Effects of Gabapentin on KCNQ5 channels

    Supplementary Table 7 - Summary of Effects of Gabapentin on KCNQ5 channels

    Supplementary Figure 8 - Effects of Gabapentin on KCNQ2/KCNQ3-W265L channels

    Supplementary Table 8 - Summary of Effects of Gabapentin on KCNQ2/KCNQ3-W265L channels

    Supplementary Figure 9 - Effects of Gabapentin on KCNQ2-W236L/KCNQ3-W265L channels

    Supplementary Table 9 - Summary of Effects of Gabapentin on KCNQ2-W236L/KCNQ3-W265L channels

  View article

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics